Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
Add more filters










Publication year range
1.
Nat Aging ; 1(8): 684-697, 2021 08.
Article in English | MEDLINE | ID: mdl-34746802

ABSTRACT

A repressive chromatin state featuring trimethylated lysine 36 on histone H3 (H3K36me3) and DNA methylation suppresses cryptic transcription in embryonic stem cells. Cryptic transcription is elevated with age in yeast and nematodes, and reducing it extends yeast lifespan, though whether this occurs in mammals is unknown. We show that cryptic transcription is elevated in aged mammalian stem cells, including murine hematopoietic stem cells (mHSCs) and neural stem cells (NSCs) and human mesenchymal stem cells (hMSCs). Precise mapping allowed quantification of age-associated cryptic transcription in hMSCs aged in vitro. Regions with significant age-associated cryptic transcription have a unique chromatin signature: decreased H3K36me3 and increased H3K4me1, H3K4me3, and H3K27ac with age. Genomic regions undergoing such changes resemble known promoter sequences and are bound by TBP even in young cells. Hence, the more permissive chromatin state at intragenic cryptic promoters likely underlies increased cryptic transcription in aged mammalian stem cells.


Subject(s)
Chromatin , Hematopoietic Stem Cells , Mesenchymal Stem Cells , Neural Stem Cells , Animals , Humans , Mice , Aging/genetics , Chromatin/genetics , DNA Methylation/genetics , Embryonic Stem Cells/metabolism , Hematopoietic Stem Cells/metabolism , Neural Stem Cells/metabolism , Mesenchymal Stem Cells/metabolism , Transcription, Genetic
2.
Aging Cancer ; 2(4): 137-159, 2021 Dec.
Article in English | MEDLINE | ID: mdl-36303712

ABSTRACT

Background: Glioblastoma (GBM) is an aggressive, age-associated malignant glioma that contains populations of cancer stem cells. These glioma stem cells (GSCs) evade therapeutic interventions and repopulate tumors due to their existence in a slowly cycling quiescent state. Although aging is well known to increase cancer initiation, the extent to which the mechanisms supporting GSC tumorigenicity are related to physiological aging remains unknown. Aims: Here, we investigate the transcriptional mechanisms by which Forkhead Box O3 (FOXO3), a transcriptional regulator that promotes healthy aging, affects GSC function and the extent to which FOXO3 transcriptional networks are dysregulated in aging and GBM. Methods and results: We performed transcriptome analysis of clinical GBM tumors and observed that high FOXO3 activity is associated with gene expression signatures of stem cell quiescence, reduced oxidative metabolism, and improved patient outcomes. Consistent with these findings, we show that elevated FOXO3 activity significantly reduces the proliferation of GBM-derived GSCs. Using RNA-seq, we find that functional ablation of FOXO3 in GSCs rewires the transcriptional circuitry associated with metabolism, epigenetic stability, quiescence, and differentiation. Since FOXO3 has been implicated in healthy aging, we then investigated the extent to which it regulates common transcriptional programs in aging neural stem cells (NSCs) and GSCs. We uncover a shared transcriptional program and, most strikingly, find that FOXO3-regulated pathways are associated with altered mitochondrial functions in both aging and GBM. Conclusions: This work identifies a FOXO-associated transcriptional program that correlates between GSCs and aging NSCs and is enriched for metabolic and stemness pathways connected with GBM and aging.

3.
Nature ; 571(7764): 205-210, 2019 07.
Article in English | MEDLINE | ID: mdl-31270459

ABSTRACT

The mammalian brain contains neurogenic niches that comprise neural stem cells and other cell types. Neurogenic niches become less functional with age, but how they change during ageing remains unclear. Here we perform single-cell RNA sequencing of young and old neurogenic niches in mice. The analysis of 14,685 single-cell transcriptomes reveals a decrease in activated neural stem cells, changes in endothelial cells and microglia, and an infiltration of T cells in old neurogenic niches. T cells in old brains are clonally expanded and are generally distinct from those in old blood, which suggests that they may experience specific antigens. T cells in old brains also express interferon-γ, and the subset of neural stem cells that has a high interferon response shows decreased proliferation in vivo. We find that T cells can inhibit the proliferation of neural stem cells in co-cultures and in vivo, in part by secreting interferon-γ. Our study reveals an interaction between T cells and neural stem cells in old brains, opening potential avenues through which to counteract age-related decline in brain function.


Subject(s)
Aging/physiology , Brain/cytology , Cell Movement , Neural Stem Cells/cytology , Neurogenesis , Single-Cell Analysis , Stem Cell Niche/physiology , T-Lymphocytes/cytology , Animals , Blood , Cell Proliferation , Clone Cells/cytology , Coculture Techniques , Endothelial Cells/cytology , Interferon-gamma/metabolism , Male , Mice , Mice, Inbred C57BL , Microglia/cytology , Sequence Analysis, RNA , Signal Transduction , T-Lymphocytes/metabolism , Transcriptome/genetics
4.
Science ; 359(6381): 1277-1283, 2018 03 16.
Article in English | MEDLINE | ID: mdl-29590078

ABSTRACT

In the adult brain, the neural stem cell (NSC) pool comprises quiescent and activated populations with distinct roles. Transcriptomic analysis revealed that quiescent and activated NSCs exhibited differences in their protein homeostasis network. Whereas activated NSCs had active proteasomes, quiescent NSCs contained large lysosomes. Quiescent NSCs from young mice accumulated protein aggregates, and many of these aggregates were stored in large lysosomes. Perturbation of lysosomal activity in quiescent NSCs affected protein-aggregate accumulation and the ability of quiescent NSCs to activate. During aging, quiescent NSCs displayed defects in their lysosomes, increased accumulation of protein aggregates, and reduced ability to activate. Enhancement of the lysosome pathway in old quiescent NSCs cleared protein aggregates and ameliorated the ability of quiescent NSCs to activate, allowing them to regain a more youthful state.


Subject(s)
Aging/physiology , Cell Division , Cellular Senescence , Lysosomes/physiology , Neural Stem Cells/physiology , Animals , Mice , Mice, Inbred C57BL
5.
Nature ; 550(7675): 249-254, 2017 10 11.
Article in English | MEDLINE | ID: mdl-29022589

ABSTRACT

Adenosine-to-inosine (A-to-I) RNA editing is a conserved post-transcriptional mechanism mediated by ADAR enzymes that diversifies the transcriptome by altering selected nucleotides in RNA molecules. Although many editing sites have recently been discovered, the extent to which most sites are edited and how the editing is regulated in different biological contexts are not fully understood. Here we report dynamic spatiotemporal patterns and new regulators of RNA editing, discovered through an extensive profiling of A-to-I RNA editing in 8,551 human samples (representing 53 body sites from 552 individuals) from the Genotype-Tissue Expression (GTEx) project and in hundreds of other primate and mouse samples. We show that editing levels in non-repetitive coding regions vary more between tissues than editing levels in repetitive regions. Globally, ADAR1 is the primary editor of repetitive sites and ADAR2 is the primary editor of non-repetitive coding sites, whereas the catalytically inactive ADAR3 predominantly acts as an inhibitor of editing. Cross-species analysis of RNA editing in several tissues revealed that species, rather than tissue type, is the primary determinant of editing levels, suggesting stronger cis-directed regulation of RNA editing for most sites, although the small set of conserved coding sites is under stronger trans-regulation. In addition, we curated an extensive set of ADAR1 and ADAR2 targets and showed that many editing sites display distinct tissue-specific regulation by the ADAR enzymes in vivo. Further analysis of the GTEx data revealed several potential regulators of editing, such as AIMP2, which reduces editing in muscles by enhancing the degradation of the ADAR proteins. Collectively, our work provides insights into the complex cis- and trans-regulation of A-to-I editing.


Subject(s)
Adenosine Deaminase , Primates/genetics , RNA Editing/genetics , RNA-Binding Proteins , Adenosine Deaminase/genetics , Adenosine Deaminase/metabolism , Animals , Female , Genotype , HEK293 Cells , Humans , Male , Mice , Muscles/metabolism , Nuclear Proteins/metabolism , Organ Specificity/genetics , Proteolysis , RNA-Binding Proteins/genetics , RNA-Binding Proteins/metabolism , Spatio-Temporal Analysis , Species Specificity , Transcriptome/genetics
6.
Cell Rep ; 18(3): 777-790, 2017 01 17.
Article in English | MEDLINE | ID: mdl-28099854

ABSTRACT

Neural stem cells (NSCs) in the adult mammalian brain serve as a reservoir for the generation of new neurons, oligodendrocytes, and astrocytes. Here, we use single-cell RNA sequencing to characterize adult NSC populations and examine the molecular identities and heterogeneity of in vivo NSC populations. We find that cells in the NSC lineage exist on a continuum through the processes of activation and differentiation. Interestingly, rare intermediate states with distinct molecular profiles can be identified and experimentally validated, and our analysis identifies putative surface markers and key intracellular regulators for these subpopulations of NSCs. Finally, using the power of single-cell profiling, we conduct a meta-analysis to compare in vivo NSCs and in vitro cultures, distinct fluorescence-activated cell sorting strategies, and different neurogenic niches. These data provide a resource for the field and contribute to an integrative understanding of the adult NSC lineage.


Subject(s)
Neural Stem Cells/metabolism , Transcriptome , Algorithms , Animals , Astrocytes/cytology , Astrocytes/metabolism , Cell Differentiation , Cell Lineage , Connexin 43/genetics , Connexin 43/metabolism , Homeodomain Proteins/genetics , Homeodomain Proteins/metabolism , Ki-67 Antigen/metabolism , Mice , Neural Stem Cells/cytology , Neurogenesis , Principal Component Analysis , RNA/chemistry , RNA/genetics , RNA/metabolism , Sequence Analysis, RNA , Single-Cell Analysis , Sodium-Potassium-Exchanging ATPase/genetics , Sodium-Potassium-Exchanging ATPase/metabolism , Transcription Factors/genetics , Transcription Factors/metabolism
8.
Cell Rep ; 4(3): 477-91, 2013 Aug 15.
Article in English | MEDLINE | ID: mdl-23891001

ABSTRACT

FOXO transcription factors are central regulators of longevity from worms to humans. FOXO3, the FOXO isoform associated with exceptional human longevity, preserves adult neural stem cell pools. Here, we identify FOXO3 direct targets genome-wide in primary cultures of adult neural progenitor cells (NPCs). Interestingly, FOXO3-bound sites are enriched for motifs for bHLH transcription factors, and FOXO3 shares common targets with the proneuronal bHLH transcription factor ASCL1/MASH1 in NPCs. Analysis of the chromatin landscape reveals that FOXO3 and ASCL1 are particularly enriched at the enhancers of genes involved in neurogenic pathways. Intriguingly, FOXO3 inhibits ASCL1-dependent neurogenesis in NPCs and direct neuronal conversion in fibroblasts. FOXO3 also restrains neurogenesis in vivo. Our study identifies a genome-wide interaction between the prolongevity transcription factor FOXO3 and the cell-fate determinant ASCL1 and raises the possibility that FOXO3's ability to restrain ASCL1-dependent neurogenesis may help preserve the neural stem cell pool.


Subject(s)
Forkhead Transcription Factors/metabolism , Neural Stem Cells/physiology , Neurogenesis/physiology , Adult Stem Cells/cytology , Adult Stem Cells/metabolism , Animals , Binding Sites , Cell Differentiation/physiology , Cell Growth Processes/physiology , Forkhead Box Protein O3 , Forkhead Transcription Factors/genetics , Genome , Mice , Neural Stem Cells/cytology , Neural Stem Cells/metabolism
9.
Nature ; 466(7304): 383-7, 2010 Jul 15.
Article in English | MEDLINE | ID: mdl-20555324

ABSTRACT

The plasticity of ageing suggests that longevity may be controlled epigenetically by specific alterations in chromatin state. The link between chromatin and ageing has mostly focused on histone deacetylation by the Sir2 family, but less is known about the role of other histone modifications in longevity. Histone methylation has a crucial role in development and in maintaining stem cell pluripotency in mammals. Regulators of histone methylation have been associated with ageing in worms and flies, but characterization of their role and mechanism of action has been limited. Here we identify the ASH-2 trithorax complex, which trimethylates histone H3 at lysine 4 (H3K4), as a regulator of lifespan in Caenorhabditis elegans in a directed RNA interference (RNAi) screen in fertile worms. Deficiencies in members of the ASH-2 complex-ASH-2 itself, WDR-5 and the H3K4 methyltransferase SET-2-extend worm lifespan. Conversely, the H3K4 demethylase RBR-2 is required for normal lifespan, consistent with the idea that an excess of H3K4 trimethylation-a mark associated with active chromatin-is detrimental for longevity. Lifespan extension induced by ASH-2 complex deficiency requires the presence of an intact adult germline and the continuous production of mature eggs. ASH-2 and RBR-2 act in the germline, at least in part, to regulate lifespan and to control a set of genes involved in lifespan determination. These results indicate that the longevity of the soma is regulated by an H3K4 methyltransferase/demethylase complex acting in the C. elegans germline.


Subject(s)
Caenorhabditis elegans Proteins/metabolism , Caenorhabditis elegans/physiology , Germ Cells/metabolism , Histones/metabolism , Longevity/physiology , Lysine/metabolism , Multiprotein Complexes/metabolism , Animals , Animals, Genetically Modified , Caenorhabditis elegans/enzymology , Caenorhabditis elegans/genetics , Caenorhabditis elegans Proteins/genetics , Disorders of Sex Development , Epigenesis, Genetic , Gene Expression Regulation , Gene Knockdown Techniques , Germ Cells/cytology , Histone Demethylases/genetics , Histone Demethylases/metabolism , Histone-Lysine N-Methyltransferase/genetics , Histone-Lysine N-Methyltransferase/metabolism , Histones/chemistry , Longevity/genetics , Male , Methylation , Multiprotein Complexes/chemistry , Multiprotein Complexes/genetics , Nuclear Proteins/genetics , Nuclear Proteins/metabolism , RNA Interference , Retinoblastoma-Binding Protein 2/genetics , Retinoblastoma-Binding Protein 2/metabolism
10.
Blood ; 112(8): 3373-82, 2008 Oct 15.
Article in English | MEDLINE | ID: mdl-18663146

ABSTRACT

To study the impact of oncogenic K-Ras on T-cell leukemia/lymphoma development and progression, we made use of a conditional K-Ras(G12D) murine knockin model, in which oncogenic K-Ras is expressed from its endogenous promoter. Transplantation of whole bone marrow cells that express oncogenic K-Ras into wild-type recipient mice resulted in a highly penetrant, aggressive T-cell leukemia/lymphoma. The lymphoblasts were composed of a CD4/CD8 double-positive population that aberrantly expressed CD44. Thymi of primary donor mice showed reduced cellularity, and immunophenotypic analysis demonstrated a block in differentiation at the double-negative 1 stage. With progression of disease, approximately 50% of mice acquired Notch1 mutations within the PEST domain. Of note, primary lymphoblasts were hypersensitive to gamma-secretase inhibitor treatment, which is known to impair Notch signaling. This inhibition was Notch-specific as assessed by down-regulation of Notch1 target genes and intracellular cleaved Notch. We also observed that the oncogenic K-Ras-induced T-cell disease was responsive to rapamycin and inhibitors of the RAS/MAPK pathway. These data indicate that patients with T-cell leukemia with K-Ras mutations may benefit from therapies that target the NOTCH pathway alone or in combination with inhibition of the PI3K/AKT/MTOR and RAS/MAPK pathways.


Subject(s)
Amyloid Precursor Protein Secretases/antagonists & inhibitors , Gene Expression Regulation , Genes, ras , Leukemia, T-Cell/genetics , Lymphoma, T-Cell/genetics , Receptor, Notch1/genetics , ras Proteins/physiology , Animals , Bone Marrow Cells/cytology , Cell Differentiation , Humans , Hyaluronan Receptors/biosynthesis , Mice , Mice, Transgenic , Mutation
11.
Cancer Cell ; 13(4): 311-20, 2008 Apr.
Article in English | MEDLINE | ID: mdl-18394554

ABSTRACT

We report that TG101348, a selective small-molecule inhibitor of JAK2 with an in vitro IC50 of approximately 3 nM, shows therapeutic efficacy in a murine model of myeloproliferative disease induced by the JAK2V617F mutation. In treated animals, there was a statistically significant reduction in hematocrit and leukocyte count, a dose-dependent reduction/elimination of extramedullary hematopoiesis, and, at least in some instances, evidence for attenuation of myelofibrosis. There were no apparent toxicities and no effect on T cell number. In vivo responses were correlated with surrogate endpoints, including reduction/elimination of JAK2V617F disease burden assessed by quantitative genomic PCR, suppression of endogenous erythroid colony formation, and in vivo inhibition of JAK-STAT signal transduction as assessed by flow cytometric measurement of phosphorylated Stat5.


Subject(s)
Amino Acid Substitution , Disease Models, Animal , Janus Kinase 2/antagonists & inhibitors , Janus Kinase 2/genetics , Polycythemia Vera/drug therapy , Polycythemia Vera/enzymology , Protein Kinase Inhibitors/therapeutic use , Pyrrolidines/therapeutic use , Sulfonamides/therapeutic use , Animals , Bone Marrow Transplantation , Cell Line, Tumor , Colony-Forming Units Assay , Endpoint Determination , Flow Cytometry , Hematopoietic System/cytology , Hematopoietic System/drug effects , Humans , Janus Kinase 2/metabolism , Mice , Mice, Inbred C57BL , Phenylalanine/genetics , Protein Kinase Inhibitors/pharmacokinetics , Protein Kinase Inhibitors/pharmacology , Pyrrolidines/pharmacokinetics , Signal Transduction/drug effects , Sulfonamides/pharmacokinetics , Survival Rate , Treatment Outcome , Valine/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...